[
    [
        {
            "time": "",
            "original_text": "借道18A两次冲击上市，却又退钱延遲发售！当故事无法兑现，企业如何过冬？",
            "features": {
                "keywords": [
                    "18A",
                    "上市",
                    "退钱",
                    "延迟发售",
                    "企业生存"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "借道18A两次冲击上市，却又退钱延遲发售！当故事无法兑现，企业如何过冬？",
                "Correlation": 7,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "新股精要：极具竞争力的创新驱动型生物医药公司迪哲医药",
            "features": {
                "keywords": [
                    "新股",
                    "迪哲医药",
                    "创新驱动",
                    "生物医药"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "新股精要：极具竞争力的创新驱动型生物医药公司迪哲医药",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "贝达药业董事长：公司将以40%的收入用于创新，目前有30多项在研创新药",
            "features": {
                "keywords": [
                    "贝达药业",
                    "创新投入",
                    "在研创新药"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业董事长：公司将以40%的收入用于创新，目前有30多项在研创新药",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业周报：CDE发布《以临床价值为导向的抗肿瘤药物临床研发指导原则》",
            "features": {
                "keywords": [
                    "医药生物",
                    "CDE",
                    "临床价值",
                    "抗肿瘤药物",
                    "研发指导原则"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业周报：CDE发布《以临床价值为导向的抗肿瘤药物临床研发指导原则》",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业双周报",
            "features": {
                "keywords": [
                    "医药生物",
                    "双周报"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药生物行业双周报",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 6,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 4,
                "Source_Recency": 6
            }
        }
    ]
]